clobetasol propionate
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Hand Dermatosis
Conditions
Hand Dermatosis
Trial Timeline
Oct 1, 2008 โ Jan 1, 2009
NCT ID
NCT00828464About clobetasol propionate
clobetasol propionate is a approved stage product being developed by GSK plc for Hand Dermatosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00828464. Target conditions include Hand Dermatosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00828464 | Approved | Completed |
Competing Products
17 competing products in Hand Dermatosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lebrikizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Methylprednisolone Tablet | Johnson & Johnson | Phase 2/3 | 65 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Pimecrolimus Cream 1% | Novartis | Phase 3 | 77 |
| tocilizumab + saline solution | Roche | Phase 3 | 77 |
| denosumab + Placebo | Amgen | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |
| dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smoothยฎ Udder Cream) | Bayer | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 2 | 49 |
| Ruxolitinib | Incyte | Phase 1/2 | 38 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream | Arcutis Biotherapeutics | Phase 1/2 | 36 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |